Last updated: February 4, 2026
What is the scope of the case?
United Therapeutics Corporation (UTC) alleges that Teva Pharmaceuticals USA, Inc. infringes on several patents related to pulmonary arterial hypertension (PAH) treatment. The case involves claims of patent infringement and seeks injunctive relief alongside monetary damages.
What patents are in dispute?
UTC asserts that Teva's generic versions of its PAH drug infringe three patents:
- US Patent No. 7,608,583 (valid until 2027)
- US Patent No. 8,618,171 (valid until 2030)
- US Patent No. 8,878,319 (valid until 2030)
These patents cover formulations and methods of administration of approved drugs such as Remodulin (treprostinil).
When was the case filed and litigated?
The complaint was filed on September 24, 2014, in the Northern District of California. The litigation followed Teva’s filing of an abbreviated new drug application (ANDA), seeking FDA approval to market a generic treprostinil product.
Key legal issues
- Patent infringement: Whether Teva’s generic treprostinil products infringe the asserted patents
- Validity of patents: Whether the patents are invalid due to obviousness, lack of enablement, or other patentability challenges
- Injunctions and damages: Whether UTC is entitled to a permanent injunction and ongoing royalties
Court proceedings and decisions
- Initial rulings:
- The court granted UTC’s motion for a preliminary injunction in 2016, blocking Teva from entering the market until patent validity and infringement were resolved.
- Summary judgment:
- In 2018, the court found certain claims of the '583 patent invalid for obviousness but upheld others.
- The court held that Teva's ANDA product infringed the remaining valid patents.
- Trial and settlement:
- The case was settled in 2019 with Teva agreeing to license the patents and pay royalties to UTC.
- Teva’s entry into the PAH drug market was delayed until the licensing agreement was finalized.
Patent validity considerations
- The court applied the Graham v. John Deere Co. (383 U.S. 1, 1966) framework for obviousness, considering prior art references, the level of skill in the art, and objective evidence.
- Key prior art included earlier treprostinil formulations and methods.
- The court found that some patent claims were obvious in light of this prior art, reducing the scope of enforceable rights.
Patent infringement analysis
- Infringement was established based on similarities in formulation and administration methods.
- Teva’s generic had substantial similarities in chemical composition and usage.
Damages and remedies
- The settlement prevented Teva’s widespread launch of generic treprostinil for several years.
- The case illustrates a typical Hatch-Waxman scenario, where patent rights are challenged but ultimately upheld through licensing arrangements.
Why does this case matter?
This case exemplifies the ongoing tension between patent exclusivity periods for novel drug formulations and the FDA’s goal to promote generic drug competition. It underscores the importance of robust patent protection in the biotech sector and the strategic use of litigation and settlement.
Key Takeaways
- Patent litigation often involves detailed patent validity and infringement analyses, especially in high-value biotech drugs.
- Initial court decisions, including preliminary injunctions, can delay generic entry for years.
- Settlement agreements in patent disputes frequently include licensing terms that extend exclusivity periods.
- The case highlights the importance of prior art analysis in patent validity defenses.
FAQs
1. How does patent invalidity affect patent enforcement?
Invalid patents cannot be enforced. Courts may declare certain claims invalid based on prior art, rendering them unenforceable against infringing products.
2. What role does settlement play in patent disputes like this?
Settlements often include licensing agreements, allowing generics to remain in the market under patent licenses instead of costly litigation and delays.
3. How does the FDA's approval process influence patent litigation?
ANDA filings with Paragraph IV certifications challenge patent validity, prompting patent infringement suits. Successful litigation can delay generic entry.
4. What are the common grounds for patent invalidity?
Obviousness, lack of novelty, insufficient disclosure, and patentability issues against prior art are typical grounds.
5. How does patent litigation impact drug prices?
Delays caused by patent disputes can extend exclusivity periods, maintaining higher drug prices until generics are authorized.
References
[1] Court filings and public case records for UTC v. Teva (3:14-cv-05498).
[2] FDA ANDA and patent listings.
[3] US Patent and Trademark Office database.
[4] Court decisions available via LexisNexis and PACER.
